ARYx Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ARYX research report →
Companywww.aryx.com
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs.
- CEO
- Paul Goddard
- IPO
- 2007
- Employees
- 56
- HQ
- Fremont, CA, US
Price Chart
Valuation
- Market Cap
- $16.73K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -270.76%
- ROIC
- 0.00%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-33,167,000 · -6.24%
- EPS
- $-1.21 · 26.67%
- Op Income
- $-31,238,000
- FCF YoY
- 23.45%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -7.55
- Avg Volume
- 1.12K
Get TickerSpark's AI analysis on ARYX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 10, 11 | Growth Equity Opportunities Fund, LLC | sell | 4,469,274 |
| Mar 10, 11 | DRANT RYAN D | sell | 4,469,274 |
| Mar 10, 11 | KOLLURI KRISHNA KITTU | sell | 4,469,274 |
| Mar 10, 11 | KERINS PATRICK J | sell | 4,469,274 |
| Sep 30, 10 | SIMON NICHOLAS J III | buy | 500,000 |
| Sep 30, 10 | MPM BIOVENTURES III-QP L.P. | buy | 500,000 |
| Sep 30, 10 | EVNIN LUKE | buy | 500,000 |
| Aug 13, 10 | EVNIN LUKE | buy | 500,000 |
| Aug 13, 10 | MPM BIOVENTURES III-QP L.P. | buy | 500,000 |
| Aug 13, 10 | SIMON NICHOLAS J III | buy | 500,000 |
Our ARYX Coverage
We haven't published any research on ARYX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ARYX Report →